# Recombinant Human Erythropoiet

## EPO inj 1 IU \(H/D OPD Only\)

| 藥物代碼 | IEPO1 |
| :--- | :--- |
| 適應症 | Treatment of anemia associated with chronic renal failure in pediatric & adult patients on hemodialysis & adult patients on peritoneal dialysis. Treatment of severe anemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. Treatment of anaemia in adult cancer patients receiving chemotherapy & to maintain Hb levels in adult cancer patients at risk of developing anemia during chemotherapy |
| 副作用 | Increased BP, thrombotic or vascular events. Flu-like symptoms, bone pain & chills after inj. Seizures. Skin reactions, palpebral edema. Rarely, erythroblastopenia. |
| 禁忌 | Patients who develop antibody-mediated Pure Red Cell Aplasia \(PRCA\) following treatment with any erythropoietin should not receive Eprex or any other erythropoietin . Uncontrolled hypertension. Known hypersensitivity to any of the components of Eprex. |
| 藥物保存方式 | 2-8℃ |
| 用法用量 | Chronic renal failure Adult patients Correction phase: 50 iu/kg 3 times/week IV. When necessary, dose adjustments should be made in increments of 25 iu/kg 3 times/week at intervals of at least 4 weeks until the target Hb concentration \(10-12 g/dL \) is achieved. Maintenance phase: Individualised dose. The recommended total weekly dose is 75-300 iu/kg. Pediatric patients Correction phase: 50 iu/kg 3 times/week IV. When necessary, dose adjustments should be made in increments of 25 iu/kg 3 times/week at intervals of at least 4 weeks until the target Hb concentration \(9.5-11 g/dL\) is achieved. Maintenance phase: Generally, children &lt; 30 kg require higher maintenance doses than children &gt; 30 kg & adults Cancer patients Initially 150 iu/kg 3 times/week. If after 4 weeks the Hb increase is &lt; 1 g/dL the dose should be increased to 300 iu/kg for an additional 4 weeks. |
| 肝功能異常 | 無需調整劑量  There are no dosage adjustments provided in the manufacturer's labeling. |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Contraindicated 哺乳期使用禁忌 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | 1. 本藥品為預先充填的針筒，限單次使用，給藥前須先檢查確定溶液無雜質或變色。 2. 皮下注射每次體積不可超過1 mL。如需注射較大量，應於不同部位給藥。 3. 靜脈注射時間至少須超過 1-5 分鐘。血液透析病人在透析期間，可經由透析線內一個適當的靜脈入口進行大量注射。 4. 本藥品「不可以」靜脈點滴輸注或與其他藥物混用。 |

